Global Impotence Agents Market Research Report: Forecast (2023-2028)

Market Definition

Impotence agents, also known as ED (Erectile Dysfunction) drugs or PDE-5 (phosphodiesterase type 5) inhibitors, are medications that help men achieve & maintain a penile erection sufficient for sexual activity. These agents work by blocking PDE5 and preventing the breakdown of cGMP (cyclic guanosine monophosphate), which relaxes smooth muscles in the penis’s arteries and allows a rush of blood to flow into the penis, thereby creating an erection firm enough for sexual intercourse. The most common impotence agents prescribed by healthcare professionals include Sildenafil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra), & Avanafil (Stendra).

Market Insights & Analysis: Global Impotence Agents Market (2023-28)

The Global Impotence Agents Market is projected to grow at a CAGR of around 6.8% during the forecast period, i.e., 2023-28. The market is poised for significant growth owing to the globally rising prevalence of ED (Erectile Dysfunction) owing to the increased burden of lifestyle diseases, such as atherosclerosis, hypertension, diabetes, obesity, depression, & stress, among other medical conditions, resulting in a growing demand for impotence agents.

The advent of the COVID-19 pandemic played a crucial role in augmenting the incidence of these health conditions due to sedentary lifestyles and increased stress levels among people. In addition, the rising geriatric population and the rapidly increasing alcohol & tobacco consumption are other prominent aspects amplifying the demand for ED drugs and, in turn, boding well for the impotence agents market.

Moreover, the steady growth in the number of ED devices also presents growth opportunities for the market, backed by the non-invasive nature as well as zero adverse effects of shock wave therapy. Healthcare device manufacturers are putting active emphasis on developing innovative technologies like magnetic therapy for ED management, creating new avenues for market growth. Additionally, increased investments in healthcare research on finding effective treatments are also projected to drive the global impotence agents market through 2028.

Global Impotence Agents Market Driver

Globally Rising Prevalence of Erectile Dysfunction- Sedentary lifestyles with no physical activity and unhealthy dietary habits with increased consumption of alcohol, tobacco, fast food, etc., are leading to increasing cases of chronic disorders like diabetes, cardiovascular diseases, hormonal imbalances, obesity, & blood pressure, and, in turn, augmenting the prevalence of erectile dysfunction among men worldwide. In addition, the rising number of people with depression & emotional imbalance due to hectic work schedules are also leading to the growing burden of ED, thereby driving the Global Impotence Agents Market.

Global Impotence Agents Market Possible Restraint

Lack of Awareness among People Regarding ED- Men might feel embarrassed in seeking ED treatment owing to the stigma associated, which results in lower diagnosis rates. In addition, various side effects of using ED drugs, such as headache, nasal congestion, dizziness, & diarrhea, among others, discourage people from seeking treatment or stop them from taking medicines before the prescribed course is completed. Moreover, the increasing availability of fake or counterfeit products marketed at prices lower than patented ED medications also negatively impacts the demand for impotence agents. Hence, these aspects might hamper the growth of the Global Impotence Agents Market during 2023-28.

Global Impotence Agents Market (2023-28): Segmentation Analysis

The Global Impotence Agents Market study from MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2028 at the global, regional, and national levels. Based on the analysis, the market has been further classified as:

Based on Product:

• Tablets
  • Avanafil (Stendra)
  • Sildenafil (Viagra)
  • Tadalafil (Cialis)
  • Vardenafil (Levitra)
• Injections
• Urethral Suppository

While Sildenafil (Viagra), one of the most extensively prescribed drugs for ED, holds the majority share of the impotence agents market, several other drugs like Tadalafil (Cialis) have gained traction in the global market, backed mainly by its extended duration of effectiveness, i.e., up to 36 hours, as well as its dosing flexibility. It can be taken either on-demand, i.e., as required, or daily with a lower dose. Cialis is approved by the U.S. FDA for the treatment of BPH (Benign Prostatic Hyperplasia), also known as an enlarged prostate in men. Hence, its versatility that it can be used for the treatment of both ED & BPH in men is another crucial aspect contributing to its rising popularity and, consequently, spurring growth in the global impotence agents market.

Global Impotence Agents Market (2023-28) Regional Projection:

Geographically, the Global Impotence Agents Market expands across:

• North America
• South America
• Europe
• Middle East & Africa
• Asia-Pacific

Of all regions globally, North America holds the most prominent share of the Impotence Agents Market, owing mainly to the high prevalence of ED and the well-established healthcare infrastructure, particularly in the US, coupled with the easy approvals of new treatments. A significant portion of the country's population experiences ED due to the increased burden of obesity, diabetes, & stress, among others, creating a massive demand for impotence agents.

Besides, the extensive network of hospitals, clinics, & healthcare providers in the US that facilitates easy access to world-class medical services & medications is another crucial aspect that drives the regional market. Massive investments by pharma firms in the R&D of impotence agents to introduce more effective treatments, favorable reimbursement policies for prescription drugs, and increasing number of product launches for ED treatment also bode well for the North America Impotence Agents Market.

Global Impotence Agents Industry Recent Developments:

• In June 2023, Mangoceuticals, Inc. (MangoRx), a company focused on developing, marketing, and selling multiple men’s health & wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,” announced the upcoming release of its second Mango ED product, leveraging the Company’s existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra™. The new Sildenafil-based Mango will still be compounded with Oxytocin & L-Arginine in a tasty Mango-flavored RDT (Rapid Dissolve Tablet) and individually packaged in a master pack of six tablets per package.
• In March 2023, Futura Medical launched 'Eroxon,' the first-ever drug-free ED treatment gel, in Europe, where consumers can buy it without a prescription online and in person via Belgian pharmacies.

Gain a Competitive Edge with Our Global Impotence Agents Market Report

1. Global Impotence Agents Market research report provides a detailed and thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics and make informed decisions.
2. This report also highlights current market trends and future projections, allowing businesses to identify emerging opportunities and potential challenges. By understanding market forecasts, companies can align their strategies and stay ahead of the competition.
3. Global Impotence Agents Market report aids in assessing and mitigating risks associated with entering or operating in the market.
4. The report would help in understanding the Impotence Agents Market forecast trends, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks and optimize their operations.